ストックスクリーナーアプリを入手
2.82
7.24%
-0.22
アフターアワーズ：
2.82
前日終値:
$3.04
開ける：
$3.1
24時間の取引高:
1,696
Relative Volume:
0.07
時価総額：
$9.60M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-12.42%
1か月 パフォーマンス:
-0.35%
6か月 パフォーマンス:
-24.80%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$2.81
$3.10
1週間の範囲:
$2.81
$3.30
52週間の値動き範囲:
$1.96
$6.60
Cosciens Biopharma Inc Stock (CSCI) Company Profile
CSCI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CSCI
Cosciens Biopharma Inc
|
2.82 | 9.60M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Cosciens Biopharma Inc (CSCI) 最新ニュース
Why COSCIENS Biopharma Inc. (CSCI) Went Down On Thursday? - Insider Monkey
COSCIENS Biopharma flags potential reporting delay By Investing.com - Investing.com Australia
Thursday’s 10 Worst-Performing Stocks - Insider Monkey
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Sector Update: Health Care Stocks Edge Higher Late Afternoon -March 20, 2025 at 04:02 pm EDT - MarketScreener
Top Midday Decliners -March 20, 2025 at 02:10 pm EDT - Marketscreener.com
COSCIENS Biopharma flags potential reporting delay - Investing.com
COSCIENS Biopharma Faces Potential Delay in Year-End Filings Due to Merger Complexities - TipRanks
Material Control Issues Force COSCIENS to Delay Critical Financial Reports - StockTitan
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents - The Manila Times
COSCIENS Biopharma Inc. Announces Potential Delay in Annual Financial Filing Due to Audit Complexities - Nasdaq
Cosciens Biopharma announces possible delay in filing 2024-end documents - TipRanks
Material Control Issues Force COSCIENS to Delay Critical Financial Filings Until Q2 - StockTitan
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last We - Asianet Newsable
1 Growth Stock Down 45% to Buy Right Now, According to Wall Street - The Globe and Mail
COSCIENS advances to Phase 2a study for inflammation treatment By Investing.com - Investing.com Australia
CSCI stock touches 52-week low at $2.28 amid market challenges - Investing.com
CSCI stock touches 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
COSCIENS Biopharma Advances Avenanthramides to Phase 2a Trial - TipRanks
COSCIENS advances to Phase 2a study for inflammation treatment - Investing.com India
Cosciens Biopharma to Start Phase 2a of Inflammation Drug Candidate -March 13, 2025 at 08:21 am EDT - Marketscreener.com
Cosciens Biopharma's early-stage study of anti-inflammatory treatment shows positive results, to start mid-stage study to test efficacy - Marketscreener.com
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product - The Manila Times
COSCIENS Biopharma Initiates Phase 2a Clinical Efficacy Study for Avenanthramides Product Following Successful Phase 1 Safety Results - Nasdaq
Cosciens Biopharma announces initiation of Phase 2a study for avenanthramides - TipRanks
Septerna pulls lead hypoparathyroidism drug on bilirubin levels - BioWorld Online
COSCIENS Biopharma halts investment in macimorelin; CMO to depart - Seeking Alpha
COSCIENS Biopharma Focuses on Natural Product Growth - TipRanks
Cosciens Biopharma provides update, reiterates pipeline prioritization - TipRanks
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization - GlobeNewswire
COSCIENS Biopharma Discontinues Key Drug Trial, Pivots to Natural Products Pipeline - StockTitan
CSCI stock touches 52-week low at $2.61 amid market challenges - Investing.com Australia
CSCI stock touches 52-week low at $2.61 amid market challenges By Investing.com - Investing.com South Africa
COSCIENS Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
This Biopharma Stock Could Be 2025’s Biggest Comeback Story - Wealth Awesome
Aeterna Zentaris : to Present at Upcoming Biotech Showcase Conference in San Francisco - Marketscreener.com
CSCI stock touches 52-week low at $2.8 amid market challenges - Investing.com Canada
CSCI stock touches 52-week low at $2.8 amid market challenges By Investing.com - Investing.com South Africa
Canada Market's top losers: Draganfly Inc. with 13.78% drop, Digihost Technology Inc, 11.42% - Business Upturn
COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023) - Yahoo Finance
COSCIENS Biopharma: Q3 Earnings Snapshot - The Pioneer
Cosciens Biopharma Inc (CSCI) 財務データ
Cosciens Biopharma Inc (CSCI) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):